Solid Biosciences Inc.
corporate_fare Company Profile
Solid Biosciences Inc. (NASDAQ:SLDB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for SLDB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for SLDB spans SCHEDULE 13D/A, 8-K, 10-Q, PRE 14A.
Recent high-impact activity:
- Perceptive Advisors Lifts Solid Biosciences Stake to 11.2% with $0.001 Pre-Funded Warrants
- Solid Biosciences Replaces Exhausted $85M ATM with New $200M Equity Program
- Solid Biosciences Q2 Loss Widens to $54.8M, Cash Runway Extended to Mid-2028
- RA Capital Management Boosts Stake in Solid Biosciences with $22M Share Purchase
- Shareholders Approve Doubling Authorized Common Stock to 480 Million Shares
Financial Snapshot
Short Interest & Short Volume
19.63 days to coverFINRA reported short interest of 17,106,152 shares in SLDB as of the September 15, 2026 settlement, a 4.4% increase from the prior period — about 19.6 days to cover at its recent average daily volume. On October 7, 2026, 66.2% of SLDB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SLDB, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
New $200M ATM Program Established · Prior $85M ATM Fully Drawn
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →